Bremelanotide PT 141 | CAS:189691-06-3

We serve Bremelanotide PT 141 CAS:189691-06-3 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Bremelanotide PT 141

Chemical Name:Bremelanotide PT 141
CAS.NO:189691-06-3
Synonyms:Bremelanotide PT 141
Bremelanotide Acetate
bremelanotide
 
Physical and Chemical Properties:
Density 1.4±0.1 g/cm3
Molecular Formula C50H68N14O10
Molecular Weight 1025.163
Index of Refraction 1.679
 
Specification:
Appearance:White to off-white powder
Assay:≥98.0%
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Bremelanotide, formerly known as PT-141, is a peptide drug. Similarly to its analogues α-MSH and melanotan II, bremelanotide acts as a non-selective agonist of all of the melanocortin receptors except MC2.



Contact us for information like Bremelanotide PT 141 chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,bremelanotide physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,Bremelanotide PT 141 Use and application,bremelanotide technical grade,usp/ep/jp grade.


Related News: Taiwan previously participated as an observer at the World Health Assembly, the W.H.O.’s governing body.7-Chloro-5-phenyl-1H-benzo[e]-[1,4]diazepine-2(3H)-thione manufacturer The 2003 outbreak of SARS killed 774 people across dozens of countries, mostly in Asia, and the current outbreak is considered to be more closely related to that virus than any other.2-chloro-5-methylpyridin-3-amine supplier The 2003 outbreak of SARS killed 774 people across dozens of countries, mostly in Asia, and the current outbreak is considered to be more closely related to that virus than any other.4-Amino-2-Fluorobenzotrifluoride vendor “No two studies are the same, and each carries its own unique risks and presents individual challenges, but the aim of CTSuccess is to use the experience we have as a company in supplying materials for thousands of trials to identify the characteristics of a project upfront and highlight potential risk factors that may arise,” said Kristen Devito, Global Director, Catalent Clinical Supply Services.However, in the long run, as the bulk API market continues to fall, more and more companies will transition to specialty API companies, and competition will intensify in the future.